LB Pharmaceuticals Announces Presentation at 25th Annual Needham Virtual Healthcare Conference
Rhea-AI Summary
LB Pharmaceuticals (Nasdaq: LBRX) announced that CEO Heather Turner will present at the 25th Annual Needham Virtual Healthcare Conference on April 16, 2026 at 11:45 a.m. ET. A live webcast and replay will be available on the company’s Investors > Events webpage.
The presentation provides an opportunity to hear management discuss business progress and strategy for LB Pharmaceuticals' late-stage neuropsychiatric therapy programs.
Positive
- None.
Negative
- None.
News Market Reaction – LBRX
On the day this news was published, LBRX declined 7.42%, reflecting a notable negative market reaction. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $58M from the company's valuation, bringing the market cap to $721.17M at that time.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD) and other neuropsychiatric diseases, today announced that Heather Turner, Chief Executive Officer, will present at the 25th Annual Needham Virtual Healthcare Conference on Thursday, April 16, 2026, at 11:45 a.m. ET.
A live webcast of the presentation will be available on the “Investors” page under the “Events” section of the Company’s website at https://ir.lbpharma.us/investors/events/, where a replay of the webcast will be archived.
About LB Pharmaceuticals
LB Pharmaceuticals is a late-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, adjunctive MDD, and other neuropsychiatric diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a wide range of neuropsychiatric diseases.
Media and Investor Contact
Ellen Rose
erose@lbpharma.us
